Synonyms: Benlysta® | hBlySmAb-1.1 | LimphoStat-B | lymphostat-B
belimumab is an approved drug (FDA (2011), EMA (2011))
Compound class:
Antibody
Comment: Belimumab is a monoclonal antibody targeting TNFSF13B (BAFF; BLyS) [1,5] , an immunostimulant essential for normal B cell maintenance and humoral immunity [6], and which is reported to be elevated in systemic lupus erythematosus (SLE) and other autoimmune diseases.
View more information in the IUPHAR Pharmacology Education Project: belimumab |
Classification | |
Compound class | Antibody |
Approved drug? | Yes (FDA (2011), EMA (2011)) |
International Nonproprietary Names | |
INN number | INN |
8381 | belimumab |
Synonyms |
Benlysta® | hBlySmAb-1.1 | LimphoStat-B | lymphostat-B |
Database Links | |
Specialist databases | |
IMGT/mAb-DB | 266 |
Other databases | |
GtoPdb PubChem SID | 178103469 |
PubChem SID | 178103469 |
Search PubMed clinical trials | belimumab |
Search PubMed titles | belimumab |
Search PubMed titles/abstracts | belimumab |
Wikipedia | Belimumab |